DRG Epidemiology’s coverage of osteopenia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of osteopenia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology’s osteopenia forecast will answer the following questions:
- Of all people with osteopenia, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with osteopenia, how many in each country of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of osteopenia over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following osteopenia patient populations:
- Total prevalent cases.
- Total prevalent cases by diagnosis
- Diagnosed prevalent cases by drug-treatment
Note: Coverage may vary by country and region.
- Osteopenia - Epidemiology - Emerging Markets
Author(s): Sunali D. Goonesekera, SM
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.
Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.